Tables
- TABLE 1
Bronchiectasis group trial end-points
Exacerbation end-points HFNT Control Rate ratio (95% CI) p-value Rate, number per patient per year 2.39 3.48 0.69 (0.49, 0.97) 0.034 Annual exacerbation days (geometric mean) 10.3 29.9 0.32 (0.14, 1.02) 0.056 Days to first exacerbation (predicted median) 84 54 0.70# (0.35, 1.40) 0.316 Secondary end-points Change from baseline Difference (95% CI) p-value HFNT Control FEV1 L 0.145 0.035 0.11 (−0.037, 0.257) 0.139 FVC L 0.115 −0.104 0.22 (−0.031, 0.468) 0.084 St George's respiratory questionnaire score¶ Total −12.3 −1.2 −11.0 (−20.7, −1.3) 0.028 Symptoms −16.9 −9.8 −7.1 (−21.0, 6.8) 0.308 Activity −6.3 3.3 −9.6 (−20.7, 1.5) 0.087 Impacts −14.7 −1.6 −13.1 (−23.7, −2.4) 0.018 6-minute walk distance m −16.2 −33.3 −17.1 (−62.3, 28.1) 0.445 HFNT: high-flow nasal therapy; FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity. #: hazard ratio; ¶: scores range from 0 to 100, with low scores indicating improvement; a change of four or more units is deemed clinically meaningful.
Vol 7 Issue 1
Table of Contents
The role of high-flow nasal therapy in bronchiectasis: a post hoc analysis
